These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
197 related articles for article (PubMed ID: 11514369)
21. Matrix metalloproteinases and tissue inhibitors of metalloproteinases in synovial fluids of patients with temporomandibular joint osteoarthritis. Kanyama M; Kuboki T; Kojima S; Fujisawa T; Hattori T; Takigawa M; Yamashita A J Orofac Pain; 2000; 14(1):20-30. PubMed ID: 11203734 [TBL] [Abstract][Full Text] [Related]
22. Combined evaluation of matrix metalloproteinases and their inhibitors has better clinical utility in oral cancer. Singh RD; Nilayangode H; Patel JB; Shah FD; Shukla SN; Shah PM; Patel PS Int J Biol Markers; 2011; 26(1):27-36. PubMed ID: 21337314 [TBL] [Abstract][Full Text] [Related]
23. The impact of matrix metalloproteinases and their tissue inhibitors in inflammatory bowel diseases. Lakatos G; Hritz I; Varga MZ; Juhász M; Miheller P; Cierny G; Tulassay Z; Herszényi L Dig Dis; 2012; 30(3):289-95. PubMed ID: 22722554 [TBL] [Abstract][Full Text] [Related]
24. The association of vascular endothelial growth factor, metalloproteinases and their tissue inhibitors with cardiovascular risk factors in the metabolic syndrome. Erman H; Gelisgen R; Cengiz M; Tabak O; Erdenen F; Uzun H Eur Rev Med Pharmacol Sci; 2016; 20(6):1015-22. PubMed ID: 27049251 [TBL] [Abstract][Full Text] [Related]
26. Matrix metalloproteinase-9 in vascular lesions and endothelial regulation in Kawasaki disease. Sakata K; Hamaoka K; Ozawa S; Niboshi A; Yahata T; Fujii M; Hamaoka A; Toiyama K; Nishida M; Itoi T Circ J; 2010 Aug; 74(8):1670-5. PubMed ID: 20534943 [TBL] [Abstract][Full Text] [Related]
27. Effects of hormone replacement therapy type and route of administration on plasma matrix metalloproteinases and their tissue inhibitors in postmenopausal women. Lewandowski KC; Komorowski J; Mikhalidis DP; Bienkiewicz M; Tan BK; O'Callaghan CJ; Lewinski A; Prelevic G; Randeva HS J Clin Endocrinol Metab; 2006 Aug; 91(8):3123-30. PubMed ID: 16705077 [TBL] [Abstract][Full Text] [Related]
28. Simultaneous up-regulation of matrix metalloproteinases 1, 2, 3, 7, 8, 9 and tissue inhibitors of metalloproteinases 1, 4 in serum of patients with chronic obstructive pulmonary disease. Navratilova Z; Zatloukal J; Kriegova E; Kolek V; Petrek M Respirology; 2012 Aug; 17(6):1006-12. PubMed ID: 22591289 [TBL] [Abstract][Full Text] [Related]
29. Temporal association between circulating proteolytic, inflammatory and neurohormonal markers in patients with coronary ectasia. Finkelstein A; Michowitz Y; Abashidze A; Miller H; Keren G; George J Atherosclerosis; 2005 Apr; 179(2):353-9. PubMed ID: 15777553 [TBL] [Abstract][Full Text] [Related]
30. Plasma matrix metalloproteinase and inhibitor profiles in patients with heart failure. Wilson EM; Gunasinghe HR; Coker ML; Sprunger P; Lee-Jackson D; Bozkurt B; Deswal A; Mann DL; Spinale FG J Card Fail; 2002 Dec; 8(6):390-8. PubMed ID: 12528092 [TBL] [Abstract][Full Text] [Related]
31. Sustained activation of neutrophils in the course of Kawasaki disease: an association with matrix metalloproteinases. Biezeveld MH; van Mierlo G; Lutter R; Kuipers IM; Dekker T; Hack CE; Newburger JW; Kuijpers TW Clin Exp Immunol; 2005 Jul; 141(1):183-8. PubMed ID: 15958085 [TBL] [Abstract][Full Text] [Related]
32. TIMP1, TIMP2, and TIMP4 are increased in aqueous humor from primary open angle glaucoma patients. Ashworth Briggs EL; Toh T; Eri R; Hewitt AW; Cook AL Mol Vis; 2015; 21():1162-72. PubMed ID: 26539028 [TBL] [Abstract][Full Text] [Related]
33. Matrix Metalloproteinases and Tissue Inhibitors of Metalloproteinases Are Potential Biomarkers of Pulmonary and Extra-Pulmonary Tuberculosis. Kathamuthu GR; Kumar NP; Moideen K; Nair D; Banurekha VV; Sridhar R; Baskaran D; Babu S Front Immunol; 2020; 11():419. PubMed ID: 32218787 [TBL] [Abstract][Full Text] [Related]
34. Proteolytic imbalance is reversed after therapeutic surgery in breast cancer patients. Giannelli G; Erriquez R; Fransvea E; Daniele A; Trerotoli P; Schittulli F; Grano M; Quaranta M; Antonaci S Int J Cancer; 2004 May; 109(5):782-5. PubMed ID: 14999790 [TBL] [Abstract][Full Text] [Related]
35. Is determination of matrix metalloproteinases and their tissue inhibitors serum concentrations useful in patients with gastroenteropancreatic and bronchopulmonary neuroendocrine neoplasms? Blicharz-Dorniak J; Kos-Kudła B; Foltyn W; Kajdaniuk D; Marek B; Zemczak A; Strzelczyk J Endokrynol Pol; 2012; 63(6):470-6. PubMed ID: 23339005 [TBL] [Abstract][Full Text] [Related]
36. Matrix metalloproteinases and tissue inhibitors of metalloproteinases in sera and tissue of patients with Dupuytren's disease. Ulrich D; Hrynyschyn K; Pallua N Plast Reconstr Surg; 2003 Oct; 112(5):1279-86. PubMed ID: 14504511 [TBL] [Abstract][Full Text] [Related]
37. Altered gene expression levels of matrix metalloproteinases and their inhibitors in periodontitis-affected gingival tissue. Kubota T; Itagaki M; Hoshino C; Nagata M; Morozumi T; Kobayashi T; Takagi R; Yoshie H J Periodontol; 2008 Jan; 79(1):166-73. PubMed ID: 18166107 [TBL] [Abstract][Full Text] [Related]
38. Circulating matrix metalloproteinases and tissue metalloproteinase inhibitors in patients with idiopathic pulmonary fibrosis in the multicenter IPF-PRO Registry cohort. Todd JL; Vinisko R; Liu Y; Neely ML; Overton R; Flaherty KR; Noth I; Newby LK; Lasky JA; Olman MA; Hesslinger C; Leonard TB; Palmer SM; Belperio JA; BMC Pulm Med; 2020 Mar; 20(1):64. PubMed ID: 32171287 [TBL] [Abstract][Full Text] [Related]
39. [Significance of imbalance between matrix metalloproteinases and tissue type inhibitor of metalloproteinases in renal tubulointerstitial lesions of aging rats]. Chen RQ; Chen XM; Cui SW; Cai GY; Shi SZ; Xie YS; Lu Y; Peng LX Zhonghua Yi Xue Za Zhi; 2004 Jun; 84(11):937-42. PubMed ID: 15329283 [TBL] [Abstract][Full Text] [Related]